{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:44:14Z","timestamp":1755693854724,"version":"3.40.5"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_almed-2023-0168_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Spontaneous bacterial peritonitis is a frequent severe complication in cirrhotic patients with ascites. Carbapenem antibiotics are currently the treatment of choice for patients with hospital-acquired or healthcare-related infections. However, there is limited evidence available on the efficacy of ertapenem in cirrhotic patients with spontaneous bacterial peritonitis. As a result, the pharmacokynetics and pharmacodynamics of this antibiotic are still unknown. The objective of this study was to develop and validate measurement procedures based on liquid chromatography-tandem mass spectrometry (UHPLC-MS\/MS) to determine ertapenem concentrations in plasma and ascitic fluid.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_almed-2023-0168_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Samples were pretreated by acetronile protein-precipitation. Chromatographic separation is performed on\u00a0a C<jats:sub>18<\/jats:sub> reversed-phase Acquity<jats:sup>\u00ae<\/jats:sup>-UPLC<jats:sup>\u00ae<\/jats:sup>-BEH<jats:sup>TM<\/jats:sup> column (2.1\u00a0\u00d7\u00a0100\u00a0mm id, 1.7\u202f\u00b5m) using a non-linear gradient of water\/acetonitrile containing 0.1\u202f% of formic acid at a flow rate of 0.4\u202fmL\/min. Ertapenem and its internal standard (ertapenem-D<jats:sub>4<\/jats:sub>) are detected by tandem mass spectrometry using positive electrospray ionization and multiple reaction monitoring, and using 476.2\u00a0\u2192\u00a0346.0\/432.2 as mass transition for ertapenem and 480.2\u00a0\u2192\u00a0350.0 for its internal standard.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_almed-2023-0168_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>No significant interferences or carry-over contamination were observed. Imprecisions, absolute relative bias, matrix effects and normalized recoveries were\u00a0\u226414.5\u202f%,\u00a0\u22649.3\u202f% (92.8\u2013104.5)\u202f% and (98.8\u2013105.8)\u202f%, respectively. Chromatographic measurement procedures were linear from (0.50\u2013100)\u202fmg\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_almed-2023-0168_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The measurement procedures based on UHPLC-MS\/MS developed and validated in this study could be useful in pharmacokynetic and pharmacodynamic studies in subjects with liver cirrhosis who develop spontaneous bacterial peritonitis treated with ertapenem.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/almed-2023-0168","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T10:15:50Z","timestamp":1702980950000},"page":"173-180","source":"Crossref","is-referenced-by-count":1,"title":["Determination of ertapenem in plasma and ascitic fluid by UHPLC-MS\/MS in cirrhotic patients with spontaneous bacterial peritonitis"],"prefix":"10.1515","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-074X","authenticated-orcid":false,"given":"Ra\u00fal","family":"Rigo-Bonnin","sequence":"first","affiliation":[{"name":"Clinical Laboratory, Bellvitge University Hospital , Bellvitge Biomedical Research Institute (IDIBELL) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Amador","sequence":"additional","affiliation":[{"name":"Service of Pharmacy, Bellvitge University Hospital , Bellvitge Biomedical Research Institute (IDIBELL) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"N\u00fa\u00f1ez-G\u00e1rate","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Bellvitge University Hospital , Bellvitge Biomedical Research Institute (IDIBELL) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virg\u00ednia","family":"Mas-Bosch","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, Bellvitge University Hospital , Bellvitge Biomedical Research Institute (IDIBELL) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Padull\u00e9s","sequence":"additional","affiliation":[{"name":"Unit of Hepatology and Liver Transplant, Service of Gastroenterology , Bellvitge Biomedical Research Institute (IDIBELL) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Cobo-Sacrist\u00e1n","sequence":"additional","affiliation":[{"name":"Unit of Hepatology and Liver Transplant, Service of Gastroenterology , Bellvitge Biomedical Research Institute (IDIBELL) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Castellote","sequence":"additional","affiliation":[{"name":"Service of Pharmacy, Bellvitge University Hospital , Bellvitge Biomedical Research Institute (IDIBELL) , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"2024062617010178291_j_almed-2023-0168_ref_001","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397\u2013417. https:\/\/doi.org\/10.1002\/hep.31884.","DOI":"10.1016\/j.jhep.2010.05.004"},{"key":"2024062617010178291_j_almed-2023-0168_ref_002","doi-asserted-by":"crossref","unstructured":"Biggins, SW, Angeli, P, Garcia-Tsao, G, Gin\u00e8s, P, Ling, SC, Nadim, MK, et al.. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;74:1014\u201348. https:\/\/doi.org\/10.1002\/hep.31884.","DOI":"10.1002\/hep.31884"},{"key":"2024062617010178291_j_almed-2023-0168_ref_003","doi-asserted-by":"crossref","unstructured":"Piano, S, Singh, V, Caraceni, P, Maiwall, R, Alessandria, C, Fernandez, J, et al.. Epidemiology and effects of bacterial infections in patients\u00a0with cirrhosis worldwide. Gastroenterology 2019;156:1368\u201380. https:\/\/doi.org\/10.1053\/j.gastro.2018.12.005.","DOI":"10.1053\/j.gastro.2018.12.005"},{"key":"2024062617010178291_j_almed-2023-0168_ref_005","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez, J, Prado, V, Trebicka, J, Amoros, A, Gustot, T, Wiest, R, et al.. European Foundation for the Study of Chronic Liver Failure (EF-Clif) Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol 2019;70:398\u2013411. https:\/\/doi.org\/10.1016\/j.jhep.2018.10.027.","DOI":"10.1016\/j.jhep.2018.10.027"},{"key":"2024062617010178291_j_almed-2023-0168_ref_006","doi-asserted-by":"crossref","unstructured":"Fernandez, J, Piano, S, Bartoletti, M, Way, EQ. Management of bacterial and fungal infections in cirrhosis: the MDRO challenge. J Hepatol 2021;75:S101\u201317. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.010.","DOI":"10.1016\/j.jhep.2020.11.010"},{"key":"2024062617010178291_j_almed-2023-0168_ref_004","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez, J, Acevedo, J, Castro, M, Garc\u00eda, O, Rodr\u00edguez de Lope, C, Roca, D, et al.. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012;55:1551\u201361. https:\/\/doi.org\/10.1002\/hep.25532.","DOI":"10.1002\/hep.25532"},{"key":"2024062617010178291_j_almed-2023-0168_ref_007","doi-asserted-by":"crossref","unstructured":"Ison, M. Empiric treatment of nosocomial spontaneous bacterial peritonitis. One size does not fit all. Hepatology 2016;63:1083\u20135. https:\/\/doi.org\/10.1002\/hep.28476.","DOI":"10.1002\/hep.28476"},{"key":"2024062617010178291_j_almed-2023-0168_ref_008","doi-asserted-by":"crossref","unstructured":"Berry, AV, Kuti, JL. Pharmacodynamic thresholds for beta-lactam antibiotics: a story of mouse versus man. Front Pharmacol 2022;13:833189. https:\/\/doi.org\/10.3389\/fphar.2022.833189.","DOI":"10.3389\/fphar.2022.833189"},{"key":"2024062617010178291_j_almed-2023-0168_ref_009","doi-asserted-by":"crossref","unstructured":"Arrigucci, S, Garcea, A, Fallani, S, Cassetta, MI, Canonico, G, Tonelli, F, et al.. Ertapenem peritoneal fluid concentrations in adult surgical patients. Int J Antimicrob Agents 2009;33:371\u20133. https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.09.015.","DOI":"10.1016\/j.ijantimicag.2008.09.015"},{"key":"2024062617010178291_j_almed-2023-0168_ref_010","doi-asserted-by":"crossref","unstructured":"Rehm, S, Rentsch, KM. LC\u2013MS\/MS method for nine different antibiotics. Clin Chim Acta 2020;511:360\u20137. https:\/\/doi.org\/10.1016\/j.cca.2020.11.001.","DOI":"10.1016\/j.cca.2020.11.001"},{"key":"2024062617010178291_j_almed-2023-0168_ref_011","doi-asserted-by":"crossref","unstructured":"Decosterd, LA, Mercier, T, Ternon, B, Cruchon, S, Guignard, N, Lahrichi, S, et al.. Validation and clinical application of a multiplex high performance liquid chromatography\u2013tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections. J Chromatogr, B: Anal Technol Biomed Life Sci 2020;1157:122160. https:\/\/doi.org\/10.1016\/j.jchromb.2020.122160.","DOI":"10.1016\/j.jchromb.2020.122160"},{"key":"2024062617010178291_j_almed-2023-0168_ref_012","doi-asserted-by":"crossref","unstructured":"Hee, KH, Fisher, D, Soon-U Lee, L, Tam, VH. Development and validation of liquid chromatography\u2013tandem mass spectrometry method for the quantification of ertapenem in human serum. Pharm Anal Acta 2015;6:1000358. https:\/\/doi.org\/10.4172\/2153-2435.1000358.","DOI":"10.4172\/2153-2435.1000358"},{"key":"2024062617010178291_j_almed-2023-0168_ref_013","doi-asserted-by":"crossref","unstructured":"van Rijn, SP, Wessels, AMA, Greijdanus, B, Touw, DJ, Alffenaar, JWC. Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method. Antimicrob Agents Chemother 2014;58:3481\u20134. https:\/\/doi.org\/10.1128\/AAC.00025-14.","DOI":"10.1128\/AAC.00025-14"},{"key":"2024062617010178291_j_almed-2023-0168_ref_014","doi-asserted-by":"crossref","unstructured":"Sime, FB, Roberts, MS, Roberts, JA, Robertson, TA. Simultaneous determination of seven \u03b2-lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies. J Chromatogr, B: Anal Technol Biomed Life Sci 2014;960:134\u201344. https:\/\/doi.org\/10.1016\/j.jchromb.2014.04.029.","DOI":"10.1016\/j.jchromb.2014.04.029"},{"key":"2024062617010178291_j_almed-2023-0168_ref_015","doi-asserted-by":"crossref","unstructured":"Pickering, M, Brown, S. Quantification and validation of HPLC-UV and LC-MS assays for therapeutic drug monitoring of ertapenem in human plasma. Biomed Chromatogr 2013;27:568\u201374. https:\/\/doi.org\/10.1002\/bmc.2829.","DOI":"10.1002\/bmc.2829"},{"key":"2024062617010178291_j_almed-2023-0168_ref_016","doi-asserted-by":"crossref","unstructured":"Stevenson, JM, Patel, JH, Churchwell, MD, Vilay, AM, Depestel, DD, S\u00f6rgel, F, et al.. Ertapenem clearance during modeled continuous renal replacement therapy. Int J Artif Organs 2008;31:1027\u201334. https:\/\/doi.org\/10.1177\/039139880803101206.","DOI":"10.1177\/039139880803101206"},{"key":"2024062617010178291_j_almed-2023-0168_ref_017","doi-asserted-by":"crossref","unstructured":"Koal, T, Deters, M, Resch, K, Kaever, V. Quantification of the carbapenem antibiotic ertapenem in human plasma by a validated liquid chromatography-mass spectrometry method. Clin Chim Acta 2006;364:239\u201345. https:\/\/doi.org\/10.1016\/j.cccn.2005.07.004.","DOI":"10.1016\/j.cccn.2005.07.004"},{"key":"2024062617010178291_j_almed-2023-0168_ref_018","unstructured":"European Medicines Agency. ICH guideline M10 on bioanalytical method validation and study sample analysis, Step 5. London: European Medicines Agency; 2022. Disponible en: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf [Acceso 22 Abril 2023]."},{"key":"2024062617010178291_j_almed-2023-0168_ref_019","unstructured":"Clinical and Laboratory Standard Institute. Liquid Chromatography-mass spectrometry methods, Approved guideline CLSI C62-A). Wayne (PA); 2022."},{"key":"2024062617010178291_j_almed-2023-0168_ref_020","doi-asserted-by":"crossref","unstructured":"Nix, DE, Majumdar, AK, DiNubile, MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 2004;53:S23\u20138. https:\/\/doi.org\/10.1093\/jac\/dkh205.","DOI":"10.1093\/jac\/dkh205"},{"key":"2024062617010178291_j_almed-2023-0168_ref_021","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Centro de informaci\u00f3n online de medicamentos (CIMA) de la AEMPS [base de datos en Internet]. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2018. Disponible en: https:\/\/www.aemps.gob.es\/cima\/inicial.do [Acceso 22 Abril 2023]."},{"key":"2024062617010178291_j_almed-2023-0168_ref_022","doi-asserted-by":"crossref","unstructured":"Magdal, U, Dybk\u00e6r, R, Olesen, H. Properties and units in the clinical laboratory sciences. Part XXIII. The NPU terminology, principles, and implementation: a user\u2019s guide (IUPAC Technical Report). Pure Appl Chem 2012;84:137\u201365. https:\/\/doi.org\/10.1515\/cclm.2011.735.","DOI":"10.1351\/PAC-REP-11-05-03"}],"container-title":["Advances in Laboratory Medicine \/ Avances en Medicina de Laboratorio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2023-0168\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2023-0168\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T17:06:38Z","timestamp":1719421598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2023-0168\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,19]]},"published-print":{"date-parts":[[2024,6,26]]}},"alternative-id":["10.1515\/almed-2023-0168"],"URL":"https:\/\/doi.org\/10.1515\/almed-2023-0168","relation":{},"ISSN":["2628-491X"],"issn-type":[{"type":"electronic","value":"2628-491X"}],"subject":[],"published":{"date-parts":[[2023,12,20]]}}}